PMID: 11341360May 9, 2001Paper

Application of pressure-controlled colon delivery capsule to oral administration of glycyrrhizin in dogs

The Journal of Pharmacy and Pharmacology
N ShibataK Takada

Abstract

A colon delivery system has been used to improve the bioavailability of glycyrrhizin, a glycoside of glycyrrhetic acid. The bioavailability of glycyrrhizin is low when administered in conventional oral galenic dosage forms because glycyrrhizin is enzymatically hydrolysed both in the stomach and in the intestine. It was reasoned that if large amounts of glycyrrhizin were directly delivered to the colon, enzymatic activity should be reduced due to saturation so that intact glycyrrhizin could be absorbed into the systemic circulation. Based on this assumption, pressure-controlled colon delivery capsules (PCDCs) were used as a colon delivery system. Eight types of glycyrrhizin solution were prepared and were introduced into PCDCs. After oral administration of the test PCDCs to beagle dogs, blood samples were obtained over 24 h and plasma glycyrrhizin concentrations were measured by an HPLC method. With PCDCs containing aqueous glycyrrhizin and propylene glycol solutions, plasma glycyrrhizin levels were extremely low and the bioavailabilities of glycyrrhizin were 0.6% and 0.4%, respectively. When Labrasol was added to both types of glycyrrhizin solution, the bioavailability was improved to 4.6% for aqueous solution and 3.8% for prop...Continue Reading

References

Jan 1, 1982·Microbiology and Immunology·N AbeN Ishida
Oct 1, 1994·Biological & Pharmaceutical Bulletin·Z WangT Kimura
Sep 1, 1995·Biological & Pharmaceutical Bulletin·Z WangT Kimura
Jul 1, 1996·The Journal of Pharmacy and Pharmacology·N GardnerL Illum
May 7, 1998·Alimentary Pharmacology & Therapeutics·T G van RossumS W Schalm
Aug 1, 1998·Journal of Controlled Release : Official Journal of the Controlled Release Society·M MuraokaK Takada
Oct 8, 1999·Journal of Chromatography. B, Biomedical Sciences and Applications·C P GuillaumeB G Wolthers
Oct 21, 1999·The Journal of Pharmacy and Pharmacology·Y YoshikawaK Takada
Apr 25, 2000·Journal of Chromatography. B, Biomedical Sciences and Applications·K KogaM Murakami

❮ Previous
Next ❯

Citations

Apr 9, 2005·International Journal of Pharmaceutics·Teruko ImaiMasaki Otagiri
Jun 4, 2013·International Journal of Pharmaceutics·Alessandra MaroniAndrea Gazzaniga
Feb 13, 2002·International Journal of Pharmaceutics·Zhaopeng HuKanji Takada
Mar 7, 2002·International Journal of Pharmaceutics·Libo YangJoseph A Fix
Dec 14, 2002·International Journal of Pharmaceutics·Y V Rama PrasadKanji Takada
Dec 15, 2010·American Journal of Physiology. Gastrointestinal and Liver Physiology·Hamed LarouiDidier Merlin
Jan 5, 2011·AAPS PharmSciTech·Tin Wui WongFabio Sonvico
Mar 19, 2011·Biological & Pharmaceutical Bulletin·Kenjiro KogaKanji Takada
Jul 3, 2007·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·Kenjiro KogaKanji Takada
Nov 1, 2013·Drug Design, Development and Therapy·Kenjiro KogaNobuji Yoshikawa
Apr 11, 2008·Drug Development and Industrial Pharmacy·Alireza GhaffariMorteza Rafiee-Tehrani
May 22, 2008·Expert Opinion on Drug Delivery·Sanjay K Jain, Anekant Jain
Mar 23, 2011·Drug Development and Industrial Pharmacy·S KrenzlinJ Siepmann
Jun 18, 2004·Drug Delivery·M K Chourasia, S K Jain
Nov 30, 2007·Advanced Drug Delivery Reviews·V JanninD Marchaud
Oct 16, 2002·World Journal of Gastroenterology : WJG·Yi-Nuo PangZhi-Rong Zhang
Nov 29, 2016·Drug Discoveries & Therapeutics·Masahiro Murakami, Chie Watanabe

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiac Glycosides

Cardiac glycosides are a diverse family of naturally derived compounds that bind to and inhibit na+/k+-atpase. Discover the latest research on cardiac glycosides heres.